Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05063734 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
A Phase 2 study, sponsored by Oxurion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05063734 is a Phase 2 study that was terminated before completion, run by Oxurion. The registered enrollment target is 16 participants.
The verdict
NCT05063734, a Phase 2 study, was terminated before completion, sponsored by Oxurion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is conducted to select the THR-687 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).
Interventions
- DRUG Aflibercept
- DRUG THR-687 dose level 1
- DRUG THR-687 dose level 2
- DRUG THR-687 selected dose level
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2022-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05063734
The ClinicalTrials.gov registry entry for NCT05063734 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oxurion, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Aflibercept is the first listed.
NCT05063734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05063734 about?
NCT05063734 is a clinical study titled "A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.". This study is conducted to select the THR-687 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).
What is the current status of trial NCT05063734?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-08-27. Estimated completion is 2022-06-29.
What interventions are being tested in trial NCT05063734?
The interventions under investigation include: Aflibercept (DRUG), THR-687 dose level 1 (DRUG), THR-687 dose level 2 (DRUG), THR-687 selected dose level (DRUG).
Who is sponsoring clinical trial NCT05063734?
This trial is sponsored by Oxurion, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.